OncoCyte (NYSEAMERICAN:OCX) had its target price lowered by Benchmark from $7.00 to $6.00 in a report released on Thursday, BenzingaRatingsTable reports. The firm currently has a speculative buy rating on the biotechnology company’s stock.
Several other equities analysts have also recently issued reports on the company. Chardan Capital cut OncoCyte from a buy rating to a neutral rating and reduced their price objective for the stock from $7.75 to $2.00 in a report on Tuesday, June 30th. Needham & Company LLC started coverage on shares of OncoCyte in a research report on Tuesday, June 30th. They issued a buy rating and a $4.00 price objective on the stock. Lake Street Capital dropped their target price on shares of OncoCyte from $6.00 to $4.00 and set a buy rating for the company in a report on Tuesday, June 30th. Piper Sandler cut shares of OncoCyte from an overweight rating to a neutral rating in a research report on Tuesday, June 30th. Finally, Zacks Investment Research upgraded shares of OncoCyte from a hold rating to a buy rating and set a $1.50 price target on the stock in a research report on Wednesday, July 15th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $4.17.
Shares of OCX opened at $1.35 on Thursday. OncoCyte has a 52-week low of $1.20 and a 52-week high of $3.51.
OncoCyte (NYSEAMERICAN:OCX) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.04 million.
A number of large investors have recently added to or reduced their stakes in OCX. Geode Capital Management LLC grew its stake in shares of OncoCyte by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 312,765 shares of the biotechnology company’s stock valued at $703,000 after buying an additional 7,073 shares in the last quarter. JPMorgan Chase & Co. grew its position in OncoCyte by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 36,905 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 8,933 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in OncoCyte in the first quarter valued at approximately $26,000. UBS Group AG lifted its position in shares of OncoCyte by 28.7% during the fourth quarter. UBS Group AG now owns 55,370 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 12,364 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of OncoCyte in the first quarter valued at $32,000.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.